Trial

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

Study Director
Fran Pappas & Antonio Lombardi
Start Date
6 / 2020
Trial Phase
Phase I
Trial Status
published
Current Enrollment
Target Enrollment
96 Participants
Overview

This study is a two-part, partially blinded, placebo controlled, combined single ascending dose (SAD) with food-effect and multiple ascending dose (MAD) study conducted in one study center in the United States.

Safety will be assessed throughout the study for all subjects. Safety assessments will include physical examinations, vital signs, serial ECGs, cardiac monitoring, adverse events (AEs), and clinical laboratory tests (including hematology, serum chemistry, coagulation, and urinalysis).

Developer Associations
Compound Associations